Hong Kong Metals and Mining Stock News

Innovent Biologics announced that its Phase 3 GLORY-2 clinical trial of mazdutide, a dual GCG/GLP-1 receptor agonist, in Chinese adults with obesity met all primary and secondary endpoints, and the company intends to submit a new drug application in China for weight management use. This marks mazdutide as the first innovative endocrinology and metabolic drug in China with clinical results published in The New England Journal of Medicine, highlighting its international scientific...

CGN Power (SEHK:1816) has kicked off full-scale construction of its Zhaoyuan Unit 1 reactor, leveraging advanced HPR1000 technology. This latest milestone signals ongoing growth ambitions and an increasingly prominent role in the nuclear power sector. See our latest analysis for CGN Power. The fresh momentum from CGN Power’s Zhaoyuan Unit 1 project comes after a year in which its share price has climbed 10.26% and total shareholder return over five years is an impressive 129.10%. This kind of...

Dalipal Holdings (SEHK:1921) has just brought its new Intelligent Production Line online at its Cangzhou facility. The production line focuses on automation, cost savings, and product quality consistency. This move also supports expansion efforts abroad, including projects in Saudi Arabia. See our latest analysis for Dalipal Holdings. Dalipal Holdings’ share price may have faced some turbulence, down 33% year-to-date, but the newly commissioned intelligent production line highlights the...

China Gas Holdings announced the appointment of Ms. Chan Pui Ling as General Counsel and Company Secretary following the resignation of Ms. Chan Wing Ki, and has hired Xiong Xin, a former senior trader at GCL Group, to lead its global LNG and LPG trading business. The company has further secured long-term LNG contracts with U.S. exporters, signaling its ambition to increase international gas trading volumes and strengthen its global supply chain. We’ll now examine how the addition of trading...

With its stock down 15% over the past three months, it is easy to disregard Xtep International Holdings (HKG:1368). But...

Sichuan Kelun-Biotech Biopharmaceutical (SEHK:6990) caught attention this week after unveiling results from several clinical studies on its core cancer therapy, sacituzumab tirumotecan, at a major oncology conference in China. See our latest analysis for Sichuan Kelun-Biotech Biopharmaceutical. Momentum around Sichuan Kelun-Biotech Biopharmaceutical has been strong, fueled in part by headline-grabbing clinical trial results and regulatory milestones for sacituzumab tirumotecan. While some...

Key Insights The projected fair value for Morimatsu International Holdings is HK$16.16 based on 2 Stage Free Cash Flow...

Akeso (SEHK:9926) has just been cleared by China’s National Medical Products Administration to initiate clinical trials for AK152, its first bispecific antibody aimed at tackling Alzheimer’s Disease, and a breakthrough in the domestic biotech space. See our latest analysis for Akeso. While Akeso's progress on Alzheimer's and its oncology advances have kept it in the headlines, the share price has pulled back 36% over the past three months after a rapid rally earlier this year. Still, the...

Samsonite Group S.A. reported its third quarter and nine-month 2025 earnings, with quarterly sales at US$872.7 million and net income reaching US$73.5 million, compared to US$877.7 million and US$66.2 million, respectively, in the prior year. While quarterly sales saw a slight decline year-on-year, the company managed to improve its quarterly net income, highlighting an increased profitability despite softer revenues. We'll now analyze how Samsonite’s improved quarterly profitability,...

Kuaishou Technology recently reported its third-quarter and nine-month 2025 results, highlighting sales of ¥35.55 billion and net income of ¥4.49 billion for the quarter, alongside updates on its share buyback program which has now reached 2.94% of shares repurchased under the ongoing plan. This strong earnings performance, coupled with ongoing capital return activities, reflects Kuaishou’s focus on operational efficiency and strengthening its market presence in the technology and social...

Vtech Holdings recently reported its earnings for the half year ended September 30, 2025, recording sales of US$991.1 million and net income of US$74.7 million, both down from the previous year, while reaffirming an interim dividend of 17.0 US cents per ordinary share. Despite anticipating improved sales in the second half of the financial year, Vtech guided that full-year revenue for 2026 is still expected to decline, signaling ongoing business challenges beyond near-term...

On November 7, 2025, CStone Pharmaceuticals presented promising preclinical data on its novel bispecific antibody, CS2015, at the ACAAI Annual Scientific Meeting in Orlando, showcasing its dual targeting of OX40L and TSLP in type 2 inflammation diseases. This marks the first time CS2015 has been presented at an international conference, highlighting potential advancements in therapies for allergies, asthma, and related conditions. We'll now explore how the innovative attributes of CS2015...

Sun Art Retail Group (SEHK:6808) just released its half-year results, revealing a drop in sales and a shift from a profit last year to a net loss. In addition, the company reduced its interim dividend per share. See our latest analysis for Sun Art Retail Group. Following the weaker half-year results and trimmed dividend, Sun Art Retail Group’s 1-year share price return is down 8.6% year-to-date, with total shareholder return over the same period falling 4.5%. Momentum appears to be fading, as...

Ascletis Pharma (SEHK:1672) revealed new preclinical data for its once-monthly combination of ASC36 and ASC35, two next-generation peptides designed for obesity treatment. Early results suggest substantially greater body weight reduction compared to standard therapies. See our latest analysis for Ascletis Pharma. Momentum for Ascletis Pharma has picked up substantially, with its 1-month share price return rocketing 51.2% and a year-to-date gain of over 340% as positive data and pipeline...

The Ximei Resources Holding Limited ( HKG:9936 ) share price has had a bad week, falling 11%. But that scarcely...

China Ruyi Holdings Limited ( HKG:136 ), is not the largest company out there, but it saw significant share price...

Viewing insider transactions for MicroPort Scientific Corporation's ( HKG:853 ) over the last year, we see that...

With its stock down 13% over the past three months, it is easy to disregard Onewo (HKG:2602). It seems that the market...

Today we're going to take a look at the well-established Orient Overseas (International) Limited ( HKG:316 ). The...

With a price-to-earnings (or "P/E") ratio of 16.5x REM Group (Holdings) Limited ( HKG:1750 ) may be sending bearish...

Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...

Key Insights Top Education Group to hold its Annual General Meeting on 27th of November Total pay for CEO Cathy Xu...

Key Insights The projected fair value for MediNet Group is HK$0.73 based on 2 Stage Free Cash Flow to Equity MediNet...

Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...